智通财经网·2026-01-13 10:07Core Viewpoint - China Biopharmaceutical (01177) announced the acquisition of Hejiya, a pioneer in siRNA innovative drug development, for a maximum consideration of RMB 120 million, aiming to enhance its innovation in chronic disease management and clinical advancement [1][2]. Group 1: Acquisition Details - The acquisition involves a full purchase of Hejiya's 100% equity by China Biopharmaceutical's wholly-owned subsidiary, with part of the payment in cash and part in shares [1]. - Hejiya will become an indirect wholly-owned subsidiary of China Biopharmaceutical upon completion of the transaction [1]. Group 2: Hejiya's Technology and Market Potential - Hejiya specializes in siRNA technology, addressing limitations in existing chronic disease therapies, with a projected global transaction volume in the siRNA field exceeding USD 35 billion by 2025, reflecting a growth rate of over 40% [2]. - Hejiya has developed a differentiated delivery platform with proprietary technology, including the MVIP platform for long-acting liver-targeted delivery, which addresses patient compliance issues in chronic disease treatment [3]. Group 3: Clinical Assets and Pipeline - Hejiya possesses four clinical-stage assets and over ten preclinical assets, all with first-in-class or best-in-class potential [4]. - Kylo-11, a long-acting Lp(a) siRNA, is in Phase II clinical trials, showing promising efficacy and safety for treating elevated Lp(a) levels, which affect over 1.4 billion people globally [4]. - Kylo-12, an APOC3 siRNA, aims for a biannual dosing regimen and is set to begin Phase II trials in 2026, targeting high triglyceride levels and familial chylomicronemia syndrome [5]. Group 4: Future Development Plans - Hejiya plans to advance multiple innovative projects into clinical stages by 2026, including products targeting obesity and Alzheimer's disease [6].